Ventas (VTR)

Real Estate · REIT - Healthcare Facilities · S&P 500
$81.86 +0.61% on the day Market cap $38.9B 52-week range $66.93 to $101.60 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
10% a year for 10 years

At a market value of $38.9B, Ventas's free cash flow of $1.3B (fiscal 2025) would need to grow about 10% a year for the stock to be worth today's price. That is faster than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Ventas's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price10.4% a year
Free cash flow, last 9 years0.4% a year
Revenue, same period6.0% a year
Price to free cash flow30.3x

Fundamental grade

C

Five factors scored 1 to 9 from VTR's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation3
Profitability3
Growth6
Financial health5
Cash efficiency9

Key numbers

P/E (trailing)145.5x
P/E (forward)129.4x
Price / free cash flow29.6x
EV / EBITDA21.8x
Price / sales6.04x
Price / book2.93x
Revenue growth+21.7%
Operating margin3.3%
Net margin4.1%
Return on equity1.8%
Dividend yield2.5%
Debt / equity0.99x

Results from SEC filings

Fiscal years, from Ventas's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$3.8B$4.1B$4.5B$4.9B$5.8B
Net income$49M-$47M-$41M$81M$251M
Free cash flow$841M$898M$860M$1.0B$1.3B
EPS (diluted)$0.13-$0.12-$0.10$0.19$0.54
Operating margin-4.2%-2.3%-2.6%-0.16%3.5%

Where the revenue comes from

Revenue by segments, fiscal 2025.

SHOP$4.3B74%
Outpatient medical and research portfolio (OM&R)$898M16%
NNN$602M10%

Superinvestors who own VTR

From each investor's latest 13F filing (what a 13F shows). 4 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Added $260M0.09%Q2 2026
Joel Greenblatt
Gotham Asset Management
Added $65M0.15%Q2 2026
Ron Baron
Baron Capital (BAMCO)
Trimmed $25M0.04%Q2 2026
Ric Dillon
Diamond Hill Capital Management
Trimmed $9M0.07%Q2 2026

Insider buying

Open-market purchases by Ventas's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Jan 29, 2026 Ro Khanna
0$76.82—
Jan 29, 2026 Ro Khanna
0$76.82—
Nov 12, 2025 Gilbert Ray Cisneros, Jr.
0$76.91—
Nov 12, 2025 Gilbert Ray Cisneros, Jr.
0$76.91—
Nov 3, 2025 Ro Khanna
0$74.11—
Nov 3, 2025 Ro Khanna
0$74.11—

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when VTR trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Ventas's stock price imply?

At a market value of $38.9B, Ventas would need its free cash flow to grow about 10% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 0% a year.

Are Ventas insiders buying the stock?

6 open-market insider purchases of VTR in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Ventas?

4 of the superinvestors Investingly tracks hold VTR in their latest 13F, including Cliff Asness, Joel Greenblatt, Ron Baron.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.